CATALYST BIOSCIENCES
Corporate Overview
15 November 2021
© Catalyst Biosciences
Forward looking statements
Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risks and uncertainties. All statements included in this presentation, other than statements of historical facts, are forward-looking statements. This press release contains forward-lookingstatements that involve substantial risks and uncertainties. Forward-lookingstatements include, without limitation, our plans to submit an IND for CB 4332 and begin clinical trials, announce a development candidate from our ProTUNE™ platform, continue to support Biogen in the development of CB 2782-PEG, and reduce the Company's burn rate by stopping development of MarzAA, as well as statements about the product candidates of Catalyst Biosciences, Inc. (the "Company") and the benefits of its protease engineering platform.
Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward- looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that clinical trials and preclinical studies may be delayed as a result of COVID-19, competitive products, and other factors, that the FDA may not agree to our clinical trial plan for CB 4332, that Biogen could terminate our agreement for the development of CB 2782-PEG, that the Company's complement degraders are not yet in human clinical trials and will require additional manufacturing validation and preclinical testing before entering human clinical trials, that the Company may need to raise additional capital, and other risks described in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 4, 2021, the Quarterly Report on Form 10-Q filed with the SEC on November 12, 2021, and in other filings filed from time to time with the SEC. The Company does not assume any obligation to update any forward-looking statements, except as required by law.
© Catalyst Biosciences
2
The Protease Medicines Company
Harnessing the catalytic power of proteases
Novel differentiated medicines
Robust complement portfolio
Unique expertise in protease engineering
© Catalyst Biosciences
3
Corporate strategy change announced 12 November
Path for long-term success
Stop MarzAA development | Focus on our protease medicines & complement |
therapeutics platform |
- MarzAA enrollment challenging
- No longer feasible to deliver topline data in 2022
- Plan to report data from MAA-304 obtained to date
- Exploring opportunities to license or sell MarzAA & DalcA
- Reduces burn rate significantly
- Programs poised to achieve several value-creating milestones in 2022 and beyond
- Move forward with CB 4332 clinical development
- Complete transfer of CBIO supported activities to Biogen for CB 2782-PEG, our C3 degrader for the potential treatment of dry AMD
- Generate candidates from our protease platform for licensing or internal development
© Catalyst Biosciences
4
Catalyst protease platform
Focus on complement therapeutics
CB 2782-PEG | CB 4332 Enhanced CFI |
Best-in-class profile for dry AMD | Restoring balance to complement |
Extended pharmacodynamics | in patients with dysregulated CFI |
Novel C3-degrader | Engineered CFI entering |
partnered to Bio for dry AMD | the clinic in 2022 |
© Catalyst Biosciences
Engineered proteases
Protease platforms tailored to restore function in specific indications
C4b C3b
ProTUNE™
PLATFORM
C3b/C4b degrader platform delivering candidates 2022
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Catalyst Biosciences Inc. published this content on 15 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 November 2021 18:14:06 UTC.